Abstract
Chemoradiation is the major treatment option in unresectable, locally advanced non-small cell lung cancer. Many clinical trials have evaluated the efficacy of different combinations of chemotherapy and radiotherapy in this heterogeneous patient population. Early clinical trials showed a survival advantage of sequential chemo-RT compared to radiation alone. Subsequent trials demonstrated that concurrent chemo-RT improved survival over sequential chemo-RT. More recent studies have suggested that there is no advantage to adding induction chemotherapy prior to concurrent chemo-RT, or to adding consolidation chemotherapy after concurrent chemo-RT. Various clinical trials have used different chemotherapy regimens, though there is still no consensus about those which are most effective. Additionally, different radiotherapeutic strategies have included hyperfractionation vs. standard fractionation, use of 3-dimensional techniques, and altering total radiation dose. As these methods are being perfected, much attention has turned toward the use of molecularly targeted therapies. This review summarizes recent clinical trials examining the role of chemo-RT in locally advanced non-small cell lung cancer and the movement toward personalized medicine.
Keywords: Locally advanced NSCLC, chemoradiation, molecularly targeted therapy
Reviews on Recent Clinical Trials
Title: Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Volume: 4 Issue: 2
Author(s): Lauren R. Mitchell, Jeffrey M. Albert and Bo Lu
Affiliation:
Keywords: Locally advanced NSCLC, chemoradiation, molecularly targeted therapy
Abstract: Chemoradiation is the major treatment option in unresectable, locally advanced non-small cell lung cancer. Many clinical trials have evaluated the efficacy of different combinations of chemotherapy and radiotherapy in this heterogeneous patient population. Early clinical trials showed a survival advantage of sequential chemo-RT compared to radiation alone. Subsequent trials demonstrated that concurrent chemo-RT improved survival over sequential chemo-RT. More recent studies have suggested that there is no advantage to adding induction chemotherapy prior to concurrent chemo-RT, or to adding consolidation chemotherapy after concurrent chemo-RT. Various clinical trials have used different chemotherapy regimens, though there is still no consensus about those which are most effective. Additionally, different radiotherapeutic strategies have included hyperfractionation vs. standard fractionation, use of 3-dimensional techniques, and altering total radiation dose. As these methods are being perfected, much attention has turned toward the use of molecularly targeted therapies. This review summarizes recent clinical trials examining the role of chemo-RT in locally advanced non-small cell lung cancer and the movement toward personalized medicine.
Export Options
About this article
Cite this article as:
Mitchell R. Lauren, Albert M. Jeffrey and Lu Bo, Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer, Reviews on Recent Clinical Trials 2009; 4 (2) . https://dx.doi.org/10.2174/157488709788185969
DOI https://dx.doi.org/10.2174/157488709788185969 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis In Vitro and In Vivo
Current Cancer Drug Targets Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening A Novel Series of N-aryltriazole and N-acridinyltriazole Hybrids as Potential Anticancer Agents
Current Organic Synthesis Regulation of HIPK Proteins by MicroRNAs
MicroRNA Novel Drug Targets in Malaria Parasite with Potential to Yield Antimalarial Drugs with Long Useful Therapeutic Lives
Current Pharmaceutical Design Tricyclic Antidepressants-loaded Biodegradable PLGA Nanoparticles: In Vitro Characterization and In Vivo Analgesic and Anti-Allodynic Effect
Current Nanoscience Chemical Profiling of <i>Chlorophytum comosum</i> (Thunb.) Jaques by GC-MS/LC-ESIMS and its Antiproliferative Effects on Human Carcinoma Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Evidence for Epigenetic Alterations in Turner Syndrome Opens up Feasibility of New Pharmaceutical Interventions
Current Pharmaceutical Design Modulation of k-Ras Signaling by Natural Products
Current Medicinal Chemistry The Mad2-Binding Protein p31<sup>comet</sup> as a Potential Target for Human Cancer Therapy
Current Cancer Drug Targets (Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening Meet Our Editorial Board Member:
The Natural Products Journal Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression
Current Cancer Drug Targets Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists
Current Respiratory Medicine Reviews β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry Star Graphs of Protein Sequences and Proteome Mass Spectra in Cancer Prediction
Current Proteomics